No Data
New Hope for Advanced Cancer Patients: SAGE Showcases Treatment-Matching via Functional Precision Oncology at AACR 2025
Earnings Preview: SAGE to Report Financial Results Post-market on April 29
Morgan Stanley Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Maintains Target Price $9
Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
Press Release: Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
Sage Alliance Schools Expands Therapeutic School to New York City Opening September 2025
Newbee4 : $Bridger Aerospace (BAER.US)$